Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)

A Study of AC5® Advanced Wound System in Patients with Lower Extremity Wounds to be Featured in a Clinical Poster

FRAMINGHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“*Arch*” or the “*Company*”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that the Company’s first commercial product, AC5^® Advanced Wound System (“AC5”), will be featured at the 2024 Symposium on Advanced Wound Care Spring Meeting (“SAWC Spring”), which takes place at Orlando Marriott World Center, Orlando, from May 14-18, 2024.On Wednesday & Thursday, May 15-16, 2024, the following clinical case, which further demonstrates the use of AC5 in patients with challenging wounds, will be presented during the poster viewing session.

*A Pilot Study of Lower Extremity Wounds Utilizing a Novel Nanoparticle Self-Assembling Peptide.*
by Eric J. Lullove, DPM, CWSP, DABLES, APWH(c), FFPM, RCPS (Glasg)
Poster #: CR-035

Arch’s team will be available for discussions with clinicians throughout the Symposium and at Arch’s booth (#535) in the exhibit hall.

Terrence W. Norchi, MD, President and CEO of Arch Therapeutics, said, “We are delighted that AC5 Advanced Wound System will be presented again at this important Symposium. Prior presentations at SAWC included a case of limb salvage in a 32 year-old patient with a necrotic spider-bite; management of post-Mohs surgery wounds; and treatment of recalcitrant wounds that previously failed to respond to other modalities. Clinicians manage a broad array of acute and chronic challenging wounds, often in patients with concurrent medical problems that interfere with healing. AC5, with its proprietary self-assembling peptide technology, presents patients and doctors an unusual mechanism of action and a different approach to wound care.”

Registration for the Symposium can be found here: https://www.hmpglobalevents.com/sawcspring/rates

AC5 is cleared by the Food and Drug Administration for the management of partial and full-thickness wounds, such as pressure sores, leg ulcers, diabetic ulcers, and surgical wounds. AC5 is a synthetic self-assembling wound care product that provides clinicians with multi-modal support and utility across all phases of wound healing. Additional information may be found here: https://www.archtherapeutics.com/technology/clinical-data.

*About Arch Therapeutics, Inc.
*Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch has received regulatory authorization to market AC5^® Advanced Wound System and AC5^® Topical Hemostat as medical devices in the United States and Europe, respectively. Arch's development stage product candidates include AC5-G™, AC5-V^® and AC5^® Surgical Hemostat, among others.^1^,^2

^1 AC5-G, AC5-V, and AC5 Surgical Hemostat are currently investigational devices limited by law to investigational use.
^2 AC5, AC5-G, AC5-V and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.

*About SAWC *
The Symposium on Advanced Wound Care meeting (“SAWC”) serves as a forum to connect the entire wound care team—physicians, podiatrists, nurses, physical therapists, researchers, scientists, and dietitians—with the foremost experts in wound care to improve patient outcomes through education. No other wound care conference offers the level of education, advanced state-of-the-art clinical reviews, and emerging research findings.

*Notice Regarding Forward-Looking Statements
*This news release contains “forward-looking statements” as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the Uplisting, the Uplisting transaction, the intended use of net proceeds from the private placement, references to novel technologies and methods, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to obtain required regulatory approvals, our ability to produce commercial quantities of our products within projected timeframes, our ability to develop and commercialize products based on our technology platform, and market conditions, and our ability to establish additional commercialization partnerships and build a critical mass of field sales representatives. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.

*Contact:*
ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Email: investors@archtherapeutics.com
Website: www.archtherapeutics.com

or

Michael Abrams
Chief Financial Officer
Arch Therapeutics, Inc.
Phone: 617-680-7841